evaluated the safety and efficacy of landiolol hydrochloride-an ultrashort-acting b1-selective blocker and highly regulated drug, positioned as a class 1 antiarrhythmic in Japan guidelines-for the prevention of AF after offpump coronary artery bypass grafting (CABG). Methods: Between January 2011 and November 2013, 116 patients underwent CABG at Fukuoka University Hospital. They were divided into two groups: group L consisted of patients who were administered landiolol hydrochloride at 2 lg/ kg/min after completion of all distal anastomoses; group C was the control group consisting of patients who were not administered landiolol. Patient backgrounds, intraoperative variables and incidence of postoperative complications were compared.
Results:
No significant between-group differences were observed in patient backgrounds or incidence of complications other than postoperative AF, which occurred significantly less frequently in group L. After administration of landiolol, heart rate decreased but no change was observed in arterial pressure or other parameters, and patient hemodynamics remained stable.
INTRODUCTION
Atrial fibrillation (AF) is the most common dysrhythmia occurring following cardiac surgery and may cause embolism or stroke, Electronic supplementary material The online version of this article (doi:10.1007/s12325-014-0158-0) contains supplementary material, which is available to authorized users. longer intensive care unit and total hospital stays, and increased health care costs [1] [2] [3] [4] [5] .
Various guidelines [6] [7] [8] [11] . Intraoperative variables are listed in Table 3 . No significant between-group differences were observed in operative duration or number of distal coronary anastomoses.
Hospital death was not observed in either group (Tables 4, 5 ). The incidences of major complications, except postoperative AF, were equivalent in the two groups; the incidence of postoperative AF was significantly lower in group L than in group C (12.2% versus 30.67%, P = 0.0263). were no between-group differences in hemodynamic parameters at any time point.
However, SBP significantly increased in both groups, and significant decreases were seen in HR (P\0.05) and CI (P\0.05) in group L. We used preoperative and postoperative oral medication (b-blocker), sex, age, body surface area, and left ventricular ejection fraction as variables in our analysis, and significant differences were associated with the administration of landiolol (P = 0.026), as listed in Table 6 .
Postoperative AF occurred in 12.2% of patients in group L and 30.7% of patients in group C (log rank P = 0.0463) (Fig. 2) ; a difference significantly associated with the use of landiolol.
DISCUSSION
Landiolol is a novel ultrashort-acting b-blocker that has a plasma half-life of 4 min [12] . In a recent randomized controlled study, Sezai et al. [13] reported that landiolol administration significantly reduced heart rate and the occurrence of AF in post-cardiac surgery patients without a significant change in blood pressure. Another prospective multi-center randomized study of landiolol in adult patients (JL-KNIGHT) [14] was recently undertaken in Japan. This drug has been widely used in Japan and has higher b1 selectivity than any currently available b-blocker, but has neither intrinsic sympathomimetic activity nor significant membrane-stabilizing activity [15] [16] [17] [18] . However, until now little information on the efficacy of intraoperative landiolol use in patients undergoing cardiac surgery has been available.
AF is one of the most frequent complications following cardiac surgery, occurring in 25% to 40% of cases [1] . Postoperative AF has been shown to result from thromboembolism, and it leads to extended ICU and hospital stays and increased medical costs [2] [3] [4] [5] . Moreover, tachyarrhythmia, of which the most common type is AF, increases myocardial oxygen consumption [19] . Previous studies have reported that postoperative AF increases the incidence of postoperative pneumonia, myocardial infarction and heart failure and, consequently, mortality. It is also considered a risk factor for myocardial ischemia because a shortened left ventricular diastolic time decreases coronary artery blood flow [20] . The utility of landiolol in preventing postoperative Data presented as n (%) or mean ± standard deviation C control, EuroSCORE European System for Cardiac Operative Risk Evaluation, L landiolol AF has been widely reported. Previous studies using b-blockers or amiodarone have reported significant reductions in postoperative AF compared with placebo; however, the incidence varied widely, from 3% to 34% [21, 22] .
In this study, among the factors previously considered risk factors for postoperative AF (including advanced age, male sex, body surface area and b-blocker use), we found age and landiolol administration to be inhibitory.
Postoperative AF was observed in only five patients in group L. Peak incidence of postoperative AF occurred in the first 2-3 days following CABG. We note, however, that not only was AF significantly inhibited during the administration of landiolol, but its occurrence Data presented as n (%) or mean ± standard deviation C control, IABP intra-aortic balloon pump, L landiolol, LITA left internal thoracic artery, RA renal artery, RITA right internal thoracic artery, SVG saphenous vein graft Data presented as mean ± standard deviation C control, L landiolol Table 5 Perioperative variables Because the half-life of the drug is short, the reason for its effect after discontinuation is unknown, as is the mechanism for inhibiting AF within 1 week, but we believe that the ability of the drug to decrease HR during the acute period and consequently stabilize hemodynamics leads to the inhibition of postoperative AF.
We believe landiolol to have a stabilizing effect during the perioperative period. However, in the present study, the safety of landiolol and the suitability of the current method of administration were studied only with regard to intraoperative administration. We believe this b-blocker can be safe and effective if appropriate administration methods are devised. It is necessary, however, to increase the number of cases and to study outcomes during the follow-up period.
LIMITATIONS
There are some limitations associated with this study. First, our study was retrospective in nature and carried out at a single institution.
The number of patients was small, because only isolated coronary surgery cases were selected. Because this drug has a very short half-life, an administration method that minimizes the occurrence of side effects should be developed. An anesthesiologist declined to use when hemodynamic Fig. 1 Measurements of systolic blood pressure, heart rate, cardiac index and systemic vascular resistance index for both groups intraoperatively and at postoperative day 1. CI cardiac index, HR heart rate, ICU intensive care unit, OPE intraoperative, POD1 postoperative day 1, SBP systolic blood pressure, SVRI systemic vascular resistance index instability. The selection criterion for patients to be treated with landiolol is the choice of anesthesiologist, and was not recorded due to the study being retrospective. We consider landiolol to be safe when it is initiated at 2 lg/kg/min intraoperatively, and we experienced no major complications with this method of administration. It will be important to carry out multi-center randomized controlled trials evaluating this rate of administration method in the future.
CONCLUSION
Landiolol, an ultrashort-acting b1-selective blocker, has a preventive effect on the development of AF after CABG surgery and may achieve successful perioperative management of patients. To further these findings, we plan to conduct a randomized prospective study to investigate the inhibitory effects of intraoperative study landiolol on postoperative AF in patients who have undergone off-pump CABG.
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